GlassScriptPhysician profile
Guadalupe Rocha
NPI 1407497076
$2,209.81
in general payments reported to CMS, 2019-2025
14 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.46 · 2022: $397 · 2023: $55.71 · 2024: $389 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $581.64 | 2022-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $328.22 | 2024-2025 | Xdemvy |
| Abbvie INC. | $227.17 | 2022-2025 | |
| Allergan, INC. | $176.65 | 2022 | |
| Dompe US, INC. | $166.52 | 2025 | Oxervate |
| Glaukos Corporation | $132.33 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Rxsight INC | $129.24 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Amgen INC. | $124.99 | 2025 | Tepezza |
| Astellas Pharma Global Development | $95.06 | 2024 | Izervay |
| Harrow Eye, LLC | $93.19 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $61.91 | 2025 | Acthar |
| Merz Pharmaceuticals, LLC | $49.46 | 2021 | |
| Thea Pharma INC. | $23.17 | 2024 | Iyuzeh |
| Bausch & Lomb Americas INC. | $20.26 | 2024 | Envista Mx60 Iol, Sofport Ao |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guadalupe Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.